Skip Navigation

Annals of Oncology 2005 16(Supplement 4):iv56-iv60; doi:10.1093/annonc/mdi909
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maiello, E.
Right arrow Articles by Colucci, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maiello, E.
Right arrow Articles by Colucci, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Invited Paper

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

E. Maiello1,2,*, V. Gebbia3, F. Giuliani1, G. Paoletti4, N. Gebbia5, N. Borsellino6, G. Cartenì7, G. Pezzella8, L. Manzione9, S. Romito10, M. Lopez4 and G. Colucci1,11

1 Oncology Institute, Bari; 2 Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo; 3 La Maddalena Hospital, Palermo; 4 Regina Elena Institute, Rome; 5 University of Palermo; 6 University of Napoli; 7 Buccheri La Ferla Hospital, Palermo; 8 Cardarelli Hospital, Naples; 9 Ospedale Nord, Taranto; 10 S. Carlo Hospital, Potenza; 11 Cardarelli Hospital, Campobasso, Italy

* Correspondence to: Dr Evaristo Maiello, Medical Oncology Unit, Casa Sollievo della Sofferenza Hospital, Viale dei Cappuccini, 71013 San Giovanni Rotondo, Italy. Tel: +39-0882-410640; Fax: +39-0882-412792; Email: e.maiello{at}operapadrepio.it

Purpose:: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy.

Patients and methods:: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180 mg/m2 on day 1 with LV5FU2 regimen (LV at 100 mg/m2 administered as a 2-hour infusion before FU at 400 mg/m2 as an intravenous bolus injection, and FU at 600 mg/m2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks.

Results:: 287 patients entered in these three trials, and 264 (92%) were evaluable for response. The overall response rate was 34.5% (95% confidence interval [CI]: 29% to 40%). When only assessable patients were analyzed, overall response rate was 37% (95% CI: 31% to 43%). Median time to progression, median duration of response and survival were 7 months, 10.5 months and 14 months, respectively. All but three patients were evaluable for toxicity which was globally mild; grade 3–4 toxicity was uncommon, and gastrointestinal disturbances were the most common.

Conclusions:: FOLFIRI regimen is effective and well-tolerated as first-line treatment in patients with advanced colorectal cancer. Further studies needed to evaluate the improvement in results with the addition of new drugs to this combination therapy.

Key words: colorectal cancer, combination therapy, folinic acid, fluorouracil, irinotecan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.